Sellas' GPS Cuts Death Risk 41% in Phase 3 Acute Myeloid Leukemia Trial
Bitget2026/11/18 03:23- Sellas Life Sciences reported positive Phase 3 REGAL results for galinpepimut-S, meeting the primary overall survival endpoint in acute myeloid leukemia.
- The maintenance vaccine significantly improved survival versus best available treatment in patients in second or later remission unable to undergo stem-cell transplantation.
- Treatment was generally well tolerated, with no new safety signals identified.
- Plans include FDA discussions on an accelerated registration strategy, with a biologics license application targeted for the first half of 2027.
- Detailed results will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays, Deutsche Bank, and others: AI boom supports the US dollar, rally expected to continue until 2027
Barclays and Deutsche Bank believe that the artificial intelligence boom will continue to support a strong US dollar.

UniCredit reaches broad agreement with Germany on the acquisition of Commerzbank
ECB President Lagarde speaks next with the Euro under 1.1000
US Pending Home Sales in October Drop to Historic Lows as High Interest Rates Continue to Suppress Housing Demand
The U.S. Pending Home Sales Index for October fell to 63, plunging 17% year-on-year and 4.7% month-on-month, reaching the lowest level on record since 2001. As a result, sales of existing homes based on contract closings have dropped to the lowest level since 2010. The chief economist of NAR stated, "Mortgage rates seem to have peaked, and October may represent the low point for contract signings in the current real estate cycle."
